Skip to content
Kempe squalene
View original picture , opens in new tab/window

Boosting the squalene content in thraustochytrids by genetic engineering using CRISPR–Cas9 System

Published: 13 December 2021

to replace the shark-based squalene as an adjuvant for COVID 2019 vaccine, Kempestiftelserna 2021-2023

For many years, shark based squalene-adjuvanted vaccines have been used to treat or prevent vital diseases such as different strains of influenza and coronaviruses (H1N1, H5N1, H7N9, H7N7, SARS-CoV, and MERS-CoV, influenza, and rabies). More than three million deep-sea sharks are estimated to be killed every year to meet the requirements of the shark liver oil market. In the proposed project, we will establish the first CRISPR-CAS 9 based genetic engineering approach to improve non-animal based squalene production in thraustochytrids to replace the COVID 19 vaccine adjuvant candidate obtained from shark.

Alok Kumar Patel

Alok Kumar Patel, Associate Senior Lecturer

Phone: +46 (0)920 491570
Organisation: Biochemical Process Engineering, Chemical Engineering, Department of Civil, Environmental and Natural Resources Engineering